FDA Accepts Supplemental NDA for CAMCEVI ETM by ACCORD
The FDA has accepted the supplemental NDA for CAMCEVI ETM, containing leuprolide mesylate.
Asset / Drug
Drug and asset intelligence for ACCORD with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Hormonal Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.